A Phase 3 interventional study of Whole Body and nasal decolonization with octenidin (Octenisan Set) and Questionnaire for study participants immediately after the decolonization in Elective Surgery, High Risk and Prevention of Surgical Site Infections, sponsored by Balgrist University Hospital. Recruiting at 2 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-08-15.
Sponsored by Balgrist University Hospital · Phase 3, Interventional, and Prevention
The general decolonization of the human body surface by industrial antiseptic agents, before elective surgery is recommended by the World Health Organization (WHO).
A specific randomized-controlled trial specifically among high-risk adult orthopedic patients for infection has not been performed.
In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision surgery and surgical site infections
The general decolonization of the human body surface and, of adjacent pathogen reservoirs such as the nose, by industrial antiseptic agents by the World Health Organization (WHO) for the risk reduction of superficial and deep surgical site infection (SSI). Such a decolonization is regarded as evidence-based in the majority of randomized, and before-after trials, since two decades, although negative studies also exist.
In the orthopedic field, this decolonization is likely to be more effective in elective patients with a proven body colonization of Staphylococcus aureus. The decolonization might be equally efeective in orthopedic patients with an inherent high risk for SSI, for which the majority of future SSI pathogens are skin commensals and S. aureus. These (eventual and future) pathogens of SSI are accessible to the topical agents during the index surgery, if the patients are well instructed and know how to decolonize themselves.
In contrast, this pre-surgical decolonization is only a supplementary measure in the bundle of all combined efforts to prevent revision surgery for infection. Its individual power is limited for young, healthy individuals, for SSIs caused by pathogens from the internal body sites (intestinal, urinary, gynecologic regions), infections acquired on the surgical ward, and in settings with less specialized surgeries and a low volume of surgical experience. Hence, in trials including all patients (or only those carrying S. aureus), the beneficial effect of decolonization can be diluted and provoke an additional costly and cumber-some organizational procedure for the majority of patients with low to moderate SSI risks.
Moreover, many surgical site infections in orthopedic surgery, especially in implant-related surgery, are more due to coagulase-negative staphylococci (CoNS) than for S. aureus.
The hallmark of the CoNS group is S. epidermidis with approximatively 70% resistance (in Switzerland) to standard prophylactic antibiotic agents9, As S. epidermidis is part of the normal human flora, typically the skin flora, and, only becomes pathogenic under certain conditions, a screening for this microorganism is not feasible in common practice,. while the prophylaxis-resistant part of all orthopedic SSI pathogens is at 30-50%.
In this single-center, prospective, randomized, and controlled superiority trial, which is planned over a period of two years, we target on an orthopedic patient population with an elevated risk for revision sur-gery and SSI; inde-pendently of a known body carriage for S. aureus.
This study will be performed with an existing "set" manufactured by Schülke \& Mayr GmbH. The "Set" was placed on the market in 2016. The distribution of Octenisan® wash lotion and Octenisan® nasal gel in the form of a set (Octenisan® Set) largely streamlines and facilitates the organizational application and compliance efforts of the study.
Academically and clinically, we will gain insight in the performance of decolonization for a patient population at particular risk of postoperative complications, where every effort to prevent infection is of importance.
6,688 studies on the registry are indexed under Infections; 807 are open to participants now.
This study's planned enrollment of 1,000 is above the median of 120 across 4,201 interventional studies indexed under Infections.
Browse Infections studies →Balgrist University Hospital is the lead sponsor of 80 studies on the registry; 14 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
This study will be performed with an existing "set" manufactured by Schülke \& Mayr GmbH. The distribution of octenisan® wash lotion and octenisan® nasal gel in the form of a set (octenisan® set) largely streamlines and facilitates the application and compliance. The duration of pre-surgical decolonization is planned to be five days. However, when this pre-surgical time period is too short, the decolonization may also start at least 3 days before surgery and be contin-ued up to 2 days post-surgery. During the post-surgery application, the patient will be washed with water and Octenisan® set by their treating nurses. The patient will also return the empty/used set and answer to a short questionnaire during their hospital stay. The study team will recuperate the questionnaire during hospitalization.
Drug: Whole Body and nasal decolonization with octenidin (Octenisan Set) · Behavioral: Questionnaire for study participants immediately after the decolonization
No Decolonization preoperatively
Octenidin body lotion once a day during the five consecutive days preceding the elective orthopedic surgery, including for the hair. Octenidin nasal creme 2-3 times a day in both nasal orifices during the same period
A questionnaire in GErman language will be handed out to decolonized patients with five questions: Practical difficulties of decolonization, the completeness of scheduled decolonization actions, all adverse events during decolonization and surgery, and two questions regarding the comprehension of the science (indication for decolonization, potential benefit expected in the individual case). The questionnaire is handmade and validated by the Investigators.
Remission (and inversely surgical site infection)
Remission is defined as the absence of clinical, anamnestic, radiologic or laboratory signs of infection.
Time frame: At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Wound problems after elective surgery
Wound problems (dehiscence, seroma, hematoma, necrosis) occurring after surgery
Time frame: Until week 6 after surgery
Unplanned revision surgery for non-infection problems in same time period
Any revision in the operating theatre due to non-infectious pathologies
Time frame: At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Adverse events
All adverse events during the decolonization and hospitalization periods
Time frame: At 6 weeks after elective orthopedic surgery; or at 1 year for surgeries with orthopedic implants
Subjective opinion and information on the decolonization
Questionnaire with 5 questions only for patients being decolonized
Time frame: A day within one week after surgery (during the hospitalization)
Plan to share: Yes — The Study Protocol will be published separately The results of the study will be a publication
Supporting information: Study protocol, Csr
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Balgrist University Hospital